Cazenave Jean-Pierre
l'Académie nationale de médecine. Etablissement Français du Sang-Alsace, UMR_S949 INSERM-Université de Strasbourg, Strasbourg, France.
Bull Acad Natl Med. 2010 Dec;194(9):1707-19; discussion 1719-20.
Transfusion of labile blood products (red cell concentrates, platelet concentrates and plasma) is vital in the absence of alternatives. Patients and doctors have always feared infections transmitted by blood, blood components and blood-derived drugs. It is potentially dangerous to delay implementation of pathogen inactivation in labile blood products pending a perfect process. Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety.
在没有其他选择的情况下，输注不稳定血液制品（红细胞浓缩物、血小板浓缩物和血浆）至关重要。患者和医生一直担心通过血液、血液成分和血液衍生药物传播的感染。在等待完美工艺的过程中，延迟对不稳定血液制品实施病原体灭活具有潜在危险。对不稳定血液制品普遍实施病原体灭活是迈向输血安全的重要一步。
